BMX-001 + Chemoradiation for Brain Cancer
(BMX-HGG Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests BMX-001, an injectable drug, added to standard radiation and chemotherapy for newly diagnosed aggressive brain cancer patients. The goal is to see if BMX-001 can improve survival and protect brain function.
Who Is on the Research Team?
Katherine Peters, MD, PhD
Principal Investigator
Duke Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a recent (within 12 weeks) surgical intervention for high-grade glioma, WHO grade III or IV. They must be ready to start standard radiation and chemotherapy, have good organ function and performance status, agree to use contraception if sexually active, and not have any severe infections or other health conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive radiation therapy and temozolomide, with BMX-001 administered subcutaneously for 8 weeks
Adjuvant Chemotherapy
Participants transition to adjuvant chemotherapy with temozolomide for 12 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMX-001
- Radiation Therapy
- Temozolomide
Radiation Therapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
BioMimetix JV, LLC
Lead Sponsor
Duke Cancer Institute
Collaborator
National Cancer Institute (NCI)
Collaborator